Abstract: The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.

Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Abstract: Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.

Abstract: The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic, wherein said compound has the general formula I: (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g.

Abstract: Polymorphic forms of deoxycytidine and methods for preparing the same are provided herein. Also provided are compositions comprising polymorphic forms of deoxycytidine and at least one residual solvent, as well as methods of treating mitochondrial diseases using said compositions.

Abstract: The invention concerns composition comprising 2?-fucosyllactose for use in the treatment of virus induced diarrhea.

Abstract: Disclose is a method of treating alphavirus infections, particularly in humans, in which pentosan polysulfate is administered to an infected subject. Whilst not effecting the viral load in a subject, the pentosan polysulfate acts to reduce inflammation in tissues, such as the muscles, and in the joints of a subject. In addition, cartilage damage in the joints may be reduced. The reduction in inflammation and/or cartilage damage acts to reduce the severe pain experienced by subjects suffering from alphavirus infections, such as Ross River virus, chikungunya virus and Barmah Forest virus.

Abstract: An early in life nutritional intervention with a lipid component having both large lipid globules with phospholipids and an increased amount of palmitic acid in the sn-2 position in triglycerides were found to improve the fatty acid composition of cell membranes, in particular brain membranes.

Abstract: The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 mL of water per gram of crosslinked carboxymethylcellulose. Steps (a) and (b) are conducted prior to or with at least one meal per day.

Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.

Abstract: A method of inhibiting or reducing inflammation in a mammal comprises administering MCP or similar Gal-3 binding moiety with honokiol in a range of about 8-10:1, by weight, MCP to honokiol. By pursuing complimentary pathways, a synergistic combination is achieved, where the reduction or degree of inflammation inhibition is greater than would be expected by the added administration of these two agents. The inflammation may be manifested as gingivitis, which may be addressed by a preparation comprising honokiol and MCP, or an MCP equivalent, in the indicated range by weight, where they are in the form of an oral rinse, lozenge, sucking candy, toothpaste or tablet.

Abstract: Compositions for regeneration of inner cells and for treating hearing loss comprise at least one modulator of mechanistic target of rapamycin (mTOR) sufficient to induce reprogramming proliferation and regeneration of inner ear cells. The composition include, in some instances, an effective amount of one or more phosphatase and tensin homolog (PTEN) inhibitors, MYC/NOTCH modulators, Atonal Homolog 1 (Atoh1) modulators or combinations thereof.

Abstract: A fixed-dose combination drug product formulated for oral delivery comprises a fixed 158.3 mg dose of clarithromycin, a fixed 13.3 mg dose of clofazimine and a fixed 40.0 mg dose of rifabutin. The fixed-dose combination drug product is sufficiently designed for use in treating pulmonary Mycobacterium avium Complex (MAC) disease in a subject in need thereof. A method for treating MAC disease in a human having MAC lung infection comprising orally administering, twice daily, about 475 mg of clarithromycin, about 40 mg of clofazimine and about 120 mg of rifabutin. A kit for treating pulmonary MAC disease in an individual having MAC lung infection comprises a supply of fixed-dose combination drug products, wherein each of the fixed-dose combination drug products comprise a fixed 158.3 mg dose of clarithromycin, a fixed 13.3 mg dose of clofazimine and a fixed 40.0 mg dose of rifabutin; and instructions for use.

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

Abstract: The present invention provides methods for alleviating pain and discomfort associated with a dry eye condition; methods for alleviating pain and discomfort while minimizing at least one skin imperfection; and methods for alleviating pain and discomfort while facilitating wound healing. The methods involve administering to a subject in need thereof a composition comprising hyaluronan with high elasticity.

Abstract: This invention relates to compositions for combating ectoparasites and endoparasites in animals, comprising eprinomectin and praziquantel in combination with a pharmaceutically acceptable carrier, and optionally an antioxidant. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

Abstract: A method of improving both motor function and cognitive function of healthy human subjects through administration of citicoline or its salt in high dosage or low dosage for a period of time, resulting in improved motor function and cognitive function.

Abstract: Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tumors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infaretion, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.

Abstract: The invention includes methods, kits, and pharmaceutical compositions for enhancing liver regeneration in a mammal in need thereof, comprising administering a therapeutically effective amount of an agent that increases nicotinamide adenine dinucleotide (NAD) activity. The methods may include administering a therapeutically effective amount of an agent that increases nicotinamide adenine dinucleotide (NAD) activity and a sirtuin 1 (Sirt1) agonist. The agent that increases NAD activity may be a NAD precursor. The NAD precursor may include one or more of tryptophan, nicotinic acid, nicotinic acid riboside, nicotinamide riboside (NR), nicotinamide, NADP, and NAD itself, and a pharmaceutically acceptable salt thereof.